High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Giving high-dose chemotherapy before a peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or by killing them. Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected and stored. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by high-dose chemotherapy and radiation therapy.

PURPOSE: This clinical trial is studying the side effects and how well high-dose chemotherapy works in treating patients undergoing stem cell transplant for recurrent or refractory Hodgkin's lymphoma.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: City of Hope Medical Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Carmustine; Cyclophosphamide; Etoposide; Melphalan

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed Hodgkin lymphoma

• Diagnosis reviewed by the participating institution

• Failed to achieve complete remission (CR) after first-line chemotherapy or chemoradiotherapy (i.e., induction failure) OR not felt to be curable by radiotherapy alone

• Relapsed after standard chemotherapy regimen for Hodgkin lymphoma AND has ≥ 1 of the following poor-risk features:

• Extranodal disease at relapse

• Interval from first CR to relapse < 12 months

• B symptoms at relapse

• Chemo-resistant relapse OR failure to achieve a second CR with conventional nontransplantation salvage chemotherapy regimen

• No cytogenetic abnormality on cytogenetic analysis of bone marrow

PATIENT CHARACTERISTICS:

Inclusion criteria:

• SWOG performance status 0-1

• LVEF > 50% by 2D-ECHO or MUGA scan

• Patients with LVEF between 45-50% and without wall motion abnormalities are assessed on an individual basis after consultation with the cardiologist

• FEV_1 or DLCO > 45% predicted

• Creatinine clearance > 60 mL/min

• HIV-negative

• Hepatitis B surface antigen-negative

• Hepatitis C virus-negative

• ALT ≤ 5 times upper limit of normal

• No inadequate vital organ function

• No active infection

• Fertile patients must use adequate contraception

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• Concurrent, post-transplantation, consolidative radiotherapy to residual masses allowed provided the patient has engrafted with a WBC > 4,000/μL and a platelet count > 100,000/μL